<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03144037</url>
  </required_header>
  <id_info>
    <org_study_id>E17086</org_study_id>
    <nct_id>NCT03144037</nct_id>
  </id_info>
  <brief_title>Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors</brief_title>
  <acronym>ALPA</acronym>
  <official_title>Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors - (AIs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center, El Paso</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Tech University Health Sciences Center, El Paso</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational trial designed to assess prospectively the adherence rate to AIs&#xD;
      among women with invasive breast cancer (stages I-III) currently receiving AI adjuvant&#xD;
      therapy after standard local and systemic therapy. We will study adherence by administrating&#xD;
      the 8-item Morisky Medication Adherence Scale (MMAS - 8).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Women with breast cancer seen at the Texas Tech Physicians Breast Care Center will be&#xD;
           recruited during their routine follow-up visit with their medical oncologist.&#xD;
&#xD;
        -  Post - menopausal women with histologically confirmed hormonal positive (ER and/or PR)&#xD;
           invasive breast cancer stages I - III with no evidence of metastatic disease (M0).&#xD;
&#xD;
        -  Patients must be on one of AI (steroidal or non-steroidal).&#xD;
&#xD;
        -  Patient must have completed local treatment (surgery /radiation) and recovered from all&#xD;
           side effects of chemotherapy and surgery.&#xD;
&#xD;
        -  Patient must be able to complete a demographic and the MMAS - 8 questionnaires in&#xD;
           English or Spanish.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2017</start_date>
  <completion_date type="Actual">March 19, 2021</completion_date>
  <primary_completion_date type="Actual">March 19, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence rate per the 8-item Morisky Medication Adherence Scale (MMAS - 8).</measure>
    <time_frame>Every 6 months for up to 24 months</time_frame>
    <description>Primary endpoint of this study is to determine the adherence rate (high, medium and low) through the MMAS-8 among early stage breast cancer patients being treated at Texas Tech University Health Sciences Center El Paso (TTUHSC EP) where the majority of the patients are of Hispanic origin.</description>
  </primary_outcome>
  <enrollment type="Actual">152</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Hispanic population is targeted, yet study is open for all those who qualify.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Post - menopausal women with histologically confirmed hormonal positive (ER and/or PR)&#xD;
             invasive breast cancer stages I - III with no evidence of metastatic disease (M0).&#xD;
&#xD;
          -  Patient must have completed local treatment (surgery /radiation) and recovered from&#xD;
             all side effects of chemotherapy and surgery.&#xD;
&#xD;
          -  Patient must be on one of AI (steroidal or non-steroidal).&#xD;
&#xD;
          -  Patient must be able to complete a demographic and the MMAS - 8 questionnaires in&#xD;
             English or Spanish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years old&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Majority of patients are females who are currently on AIs.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Philipovskiy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech University Health Sciences Center, El Paso</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Tech University HSC El Paso</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Tech University Health Sciences Center, El Paso</investigator_affiliation>
    <investigator_full_name>Alexander Philipovskiy</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 18, 2021</submitted>
    <returned>June 11, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

